AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|
20 C
New York
Tuesday, September 8, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

New ECCIA-Bain report: Europe’s high-end sector sounds alarm on tariffs, skills and competitiveness

New Report on Europe's High-End Sector Shows €986 Billion Economic Engine Powerhouse Driving Jobs, Tourism & Craftsmanship Projected global high-end & luxury market growth expected...

New ECCIA-Bain report: Europe’s high-end sector sounds alarm on tariffs, skills and competitiveness

New Report on Europe's High-End Sector Shows €986 Billion Economic Engine Powerhouse Driving Jobs, Tourism & Craftsmanship Projected global high-end & luxury market growth expected...

GoldMining Options Up to 80% of the Boa Vista Project to Australian Mines Limited for Total Consideration of Up to $7 million

VANCOUVER, BC, July 1, 2025 /CNW/ - GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD) (NYSE American: GLDG) is pleased to announce that its...

GoldMining Options Up to 80% of the Boa Vista Project to Australian Mines Limited for Total Consideration of Up to $7 million

VANCOUVER, BC, July 1, 2025 /PRNewswire/ - GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD) (NYSE American: GLDG) is pleased to announce that its...

From Runway to Radical Reinvention: Sandra Rives Launches “Unapologetically Authentic” Coaching Program for Executive Women

Creator of Red Opium unveils a transformational course helping executive women reclaim confidence, set boundaries, and speak with unapologetic clarity NEW YORK, July 1, 2025...

From Runway to Radical Reinvention: Sandra Rives Launches “Unapologetically Authentic” Coaching Program for Executive Women

Creator of Red Opium unveils a transformational course helping executive women reclaim confidence, set boundaries, and speak with unapologetic clarity NEW YORK, July 1, 2025...

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

AI on the Frontline: Global Firms Back Innovation, Brace for New Cyber Threats

New Trend Micro research reveals widespread AI adoption in cybersecurity strategies, but mounting concerns cyber risk exposure DALLAS, July 1, 2025 /PRNewswire/ -- Global AI cybersecurity...

FINREGLAB STUDY FINDS IMPROVEMENTS IN CONSUMER UNDERWRITING AND CREDIT ACCESS FROM MODELS USING MACHINE LEARNING AND CASH FLOW DATA

WASHINGTON, July 1, 2025 /PRNewswire/ -- FinRegLab today released new empirical research demonstrating that adopting machine learning techniques and incorporating cash flow data into...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers